3 unknown. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations Leflunomide, The combination of MEK inhibitor + hydroxychloroquine( plaquenil) ± bevacizumab - RAS Mutation, Ras (Kras or Nras) Gene Mutation | Phase 2 | Unknown | N.N. Petrov National Medical Research Center of Oncology | 20 | 2023-10-03 | 2024-01-29 |
| PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC oxaliplatin+capecitabine+bevacizumab+PD-1 antibody - Colorectal Cancer, RAS Mutation | Phase 2 | Unknown | Chinese PLA General Hospital | 40 | 2021-05-26 | 2024-04-30 |
| Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer Sintilimab (IBI308)+bevacizumab+oxaliplatin+capecitabine - Metastatic Colorectal Cancer, RAS Mutation | Phase 2 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 25 | 2021-02-04 | 2023-03-17 |
Colorectal Neoplasms (3) · Lung Neoplasms (1) · Melanoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
Colonic Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Intestinal Diseases (3) · Intestinal Neoplasms (3) · Neoplasms by Site (3) · Rectal Diseases (3) · Neoplasms (2) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Lung Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms, Germ Cell and Embryonal (1)
Bevacizumab (1) · Leflunomide (1) · sintilimab (1)
Chinese PLA General Hospital (1) · N.N. Petrov National Medical Research Center of Oncology (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1)
China (2) · Russia (1)
Evgeny Imyanitov (1) · Guanghai Dai, MD (1) · Ying Yuan, MD (1)